London-listed MedTech Renalytix has completed three new healthcare provider integrations in the US during the final quarter of 2025, with testing now underway at all sites.

The precision diagnostics company, which specialises in AI-enabled kidney disease testing, completed the integrations at kidney care providers in New York, Florida and Tennessee.

They embed the company’s FDA-approved and Medicare-reimbursed kidneyintelX.dkd test directly into existing clinical workflows via one-click ordering.

The New York firm expects utilisation to grow as adoption expands across patient populations.

It is also advancing its collaboration with Tempus AI to support broader electronic health record integration and future expansion, and plans further provider integrations in the coming months.